Condor Software
Condor Software develops financial management software for clinical trials in the biopharmaceutical sector. Its platform enables accounting, finance, and clinical operations teams to manage research and development spending through automated accruals, budgeting, and forecasting tools. The system integrates data from enterprise resource planning, clinical trial management, and vendor systems to provide a unified view of financial and operational data. It supports scenario planning, vendor spend tracking, and reconciliation of clinical activity with financial records to assist in financial close processes. The platform also includes data validation, audit tracking, and reporting features to help maintain compliance and transparency across clinical programs.
Condor Software develops financial management software for clinical trials in the biopharmaceutical sector. Its platform enables accounting, finance, and clinical operations teams to manage research and development spending through automated accruals, budgeting, and forecasting tools. The system integrates data from enterprise resource planning, clinical trial management, and vendor systems to provide a unified view of financial and operational data. It supports scenario planning, vendor spend tracking, and reconciliation of clinical activity with financial records to assist in financial close processes. The platform also includes data validation, audit tracking, and reporting features to help maintain compliance and transparency across clinical programs.
Condor Software has raised $24.0M across 1 round. Its most recent round was a Series A of $24.0M in Mar 2026. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Condor Software is featured in
Similar companies
Ammortal is a healthcare services company that offers bio-optimization services.
Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.
Swaza develops nanotechnology-based therapeutics designed to address critical medical conditions involving impaired oxygen delivery and tissue healing. The company focuses on a nanofluid breathing aid, AeroHeal, which delivers oxygen and removes carbon dioxide in patients with compromised lungs, eliminating the need for invasive ventilation. Their primary product, SWAZA-1, is a non-invasive nanofluid that facilitates gas exchange in damaged lungs. Additionally, SWAZA-2 is an oxygen-enriched biomaterial aimed at enhancing wound healing, and SWAZA-3 is a thermoreversible enema intended for emergency oxygenation.
A cell therapy business called Immusoft is dedicated to creating revolutionary treatments for uncommon diseases by leveraging sustained delivery of therapeutic proteins from a patient's own cells. Immune System Programming (ISPTM), a technology platform being developed by the company, alters a patient's B cells and teaches them to create gene-encoded medications. The ISP-reprogrammed B cells develop into tiny drug factories that are anticipated to live in patients for many years and give therapeutic effect. The business is based in Seattle, Washington.
Defeat the mutants.
Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Its programmes have the potential to dramatically improve patient care in major markets.
Zenas BioPharma is a company based in Florida, USA that specializes in creating immune-focused treatments for patients.
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of #cancer.
Apogee Therapeutics, a biotechnology company headquartered in San Francisco, California, was established in 2022 with a focus on developing innovative therapies for immunological and inflammatory conditions to meet the needs of patients.
Rybodyn is a biotechnology research company that develops therapeutics to train the immune system to detect and eradicate cancer internally.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.